{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:21:23Z","timestamp":1794932483789,"version":"4.9.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012543","name":"Shanghai Science and Technology Development Foundation","doi-asserted-by":"publisher","award":["PKJ2025-Y07"],"award-info":[{"award-number":["PKJ2025-Y07"]}],"id":[{"id":"10.13039\/100012543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["ZD2021CY001"],"award-info":[{"award-number":["ZD2021CY001"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["20YF1458700"],"award-info":[{"award-number":["20YF1458700"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019978","name":"Shanghai Pudong New Area Health Commission","doi-asserted-by":"publisher","award":["PW2025D-06"],"award-info":[{"award-number":["PW2025D-06"]}],"id":[{"id":"10.13039\/501100019978","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC3502000"],"award-info":[{"award-number":["2022YFC3502000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005891","name":"State Administration of Traditional Chinese Medicine of the People's Republic of China","doi-asserted-by":"publisher","award":["ZYYCXTDD-202004"],"award-info":[{"award-number":["ZYYCXTDD-202004"]}],"id":[{"id":"10.13039\/501100005891","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82374086"],"award-info":[{"award-number":["82374086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574633"],"award-info":[{"award-number":["82574633"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82141203"],"award-info":[{"award-number":["82141203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011198","name":"State Key Laboratory of Drug Research, Chinese Academy of Sciences","doi-asserted-by":"publisher","award":["SKLDR-2025-KF-01"],"award-info":[{"award-number":["SKLDR-2025-KF-01"]}],"id":[{"id":"10.13039\/501100011198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010876","name":"Shanghai University of Traditional Chinese Medicine","doi-asserted-by":"publisher","award":["2023YZZ02"],"award-info":[{"award-number":["2023YZZ02"]}],"id":[{"id":"10.13039\/501100010876","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports Medicine"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.xcrm.2026.103113","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T15:10:53Z","timestamp":1792422653000},"page":"103113","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Isobavachalcone targets deubiquitinase OTUB1 to induce PD-L1 degradation and enhances antitumor immunity"],"prefix":"10.1016","volume":"7","author":[{"given":"Qing","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanchi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dianping","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linyang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuwen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shize","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinying","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8695-0343","authenticated-orcid":false,"given":"Sanhong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xcrm.2026.103113_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.xcrm.2026.103113_bib2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103113_bib3","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus Ipilimumab in Advanced Melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103113_bib4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103113_bib5","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41571-021-00473-5","article-title":"PD-L1 as a biomarker of response to immune-checkpoint inhibitors","volume":"18","author":"Doroshow","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103113_bib6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","article-title":"Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression","volume":"19","author":"Garcia-Diaz","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/j.xcrm.2026.103113_bib7","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms Controlling PD-L1 Expression in Cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.xcrm.2026.103113_bib8","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.7150\/jca.57334","article-title":"A snapshot of the PD-1\/PD-L1 pathway","volume":"12","author":"Ghosh","year":"2021","journal-title":"J. Cancer"},{"key":"10.1016\/j.xcrm.2026.103113_bib9","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.xcrm.2026.103113_bib10","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.xcrm.2026.103113_bib11","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/ptr.8082","article-title":"Phytochemicals in regulating PD-1\/PD-L1 and immune checkpoint blockade therapy","volume":"38","author":"Zhang","year":"2024","journal-title":"Phytother Res."},{"key":"10.1016\/j.xcrm.2026.103113_bib12","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103113_bib13","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103113_bib14","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103113_bib15","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103113_bib16","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.xcrm.2026.103113_bib17","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.xcrm.2026.103113_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1001\/jamaoncol.2015.0373","article-title":"Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs","volume":"1","author":"Mailankody","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.xcrm.2026.103113_bib19","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.xcrm.2026.103113_bib20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.xcrm.2026.103113_bib21","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.ymthe.2020.12.032","article-title":"Emerging Role of Ubiquitination in the Regulation of PD-1\/PD-L1 in Cancer Immunotherapy","volume":"29","author":"Hu","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.xcrm.2026.103113_bib22","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s13046-023-02805-y","article-title":"Targeting ubiquitin specific proteases (USPs) in cancer immunotherapy: from basic research to preclinical application","volume":"42","author":"Gao","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103113_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.611","article-title":"5,7,4'-Trimethoxyflavone triggers cancer cell PD-L1 ubiquitin-proteasome degradation and facilitates antitumor immunity by targeting HRD1","volume":"5","author":"Xia","year":"2024","journal-title":"MedComm"},{"key":"10.1016\/j.xcrm.2026.103113_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70430","article-title":"Cordycepin Targets HRD1 to Promote Cancer Cell PD-L1 Ubiquitin-Proteasome Degradation and Increase Antitumor Immunity","volume":"6","author":"Geng","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.xcrm.2026.103113_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1158\/0008-5472.CAN-21-2362","article-title":"FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell-Mediated Bladder Cancer Immune Surveillance","volume":"82","author":"Jing","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.xcrm.2026.103113_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc3911","article-title":"Down-regulation of A20 promotes immune escape of lung adenocarcinomas","volume":"13","author":"Breitenecker","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.xcrm.2026.103113_bib27","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41418-022-01097-7","article-title":"SPOP mutations promote tumor immune escape in endometrial cancer via the IRF1-PD-L1 axis","volume":"30","author":"Gao","year":"2023","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xcrm.2026.103113_bib28","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2016.10.010","article-title":"Deubiquitination and Stabilization of PD-L1 by CSN5","volume":"30","author":"Lim","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.xcrm.2026.103113_bib29","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41418-020-00700-z","article-title":"Deubiquitinating enzyme OTUB1 promotes cancer cell immunosuppression via preventing ER-associated degradation of immune checkpoint protein PD-L1","volume":"28","author":"Zhu","year":"2021","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.xcrm.2026.103113_bib30","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1158\/2326-6066.CIR-18-0910","article-title":"USP22 Deubiquitinates CD274 to Suppress Anticancer Immunity","volume":"7","author":"Huang","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.xcrm.2026.103113_bib31","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.xcrm.2026.103113_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17193262","article-title":"Optimizing Anti-PD1 Immunotherapy: An Overview of Pharmacokinetics, Biomarkers, and Therapeutic Drug Monitoring","volume":"17","author":"Monteiro","year":"2025","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.xcrm.2026.103113_bib33","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.7150\/ijbs.94013","article-title":"Target deubiquitinase OTUB1 as a therapeatic strategy for BLCA via \u03b2-catenin\/necroptosis signal pathway","volume":"20","author":"Liao","year":"2024","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.xcrm.2026.103113_bib34","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.32604\/or.2025.063719","article-title":"Advances in Tumor Microenvironment and Immunotherapeutic Strategies for Hepatocellular Carcinoma","volume":"33","author":"Xue","year":"2025","journal-title":"Oncol. Res."},{"key":"10.1016\/j.xcrm.2026.103113_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103249","article-title":"Efficacy and safety of HBM4003 combined with toripalimab in refractory neuroendocrine neoplasms: a multicenter, phase II study","volume":"84","author":"Zhang","year":"2025","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.xcrm.2026.103113_bib36","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1186\/s12951-024-02936-0","article-title":"HDACi combination therapy with IDO1i remodels the tumor microenvironment and boosts antitumor efficacy in colorectal cancer with microsatellite stability","volume":"22","author":"Liang","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"10.1016\/j.xcrm.2026.103113_bib37","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1053\/j.gastro.2019.01.252","article-title":"MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1","volume":"156","author":"Li","year":"2019","journal-title":"Gastroenterology"}],"container-title":["Cell Reports Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005306?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666379126005306?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:57:42Z","timestamp":1794931062000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666379126005306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2666379126005306"],"URL":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103113","relation":{},"ISSN":["2666-3791"],"issn-type":[{"value":"2666-3791","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Isobavachalcone targets deubiquitinase OTUB1 to induce PD-L1 degradation and enhances antitumor immunity","name":"articletitle","label":"Article Title"},{"value":"Cell Reports Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xcrm.2026.103113","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103113"}}